New Equilibrium Biosciences is a biotechnology startup founded in 2019 with a mission to discover new medicines for life-threatening diseases, specifically focusing on extending the health span of patients. The company leverages a computational-experimental platform to discover lead drug candidates that regulate intrinsically disordered proteins implicated in cancers and neurodegenerative disorders. In its latest funding round on 31 March 2021, New Equilibrium Biosciences secured a $10.00M investment from RA Capital Management and Petri Bio, reflecting a strong investor confidence in the company's innovative approach and potential impact in the healthcare space. Headquartered in the United States, the company's focus on addressing critical unmet medical needs positions it as a promising player in the biotechnology industry, attracting attention from both investors and the broader healthcare community.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $10.00M | 2 |
|
31 Mar 2021 |
| Grant | $255.87K | 1 |
|
10 Sep 2020 |
| Grant | Unknown | 1 | Massachusetts Life Sciences Center | 01 May 2020 |
| Pre Seed Round | $250.00K | 1 | Petri | 01 Oct 2019 |
No recent news or press coverage available for New Equilibrium Biosciences.
We care about your data, and we'd love to use cookies make your experience better.
